| scholarly article | Q13442814 |
| P356 | DOI | 10.4155/BIO.09.177 |
| P953 | full work available at URL | https://www.tandfonline.com/doi/pdf/10.4155/bio.09.177 |
| P698 | PubMed publication ID | 21083258 |
| P2093 | author name string | Graham Lappin | |
| P2860 | cites work | Effect of oral ketoconazole on intestinal first-pass effect of midazolam and fexofenadine in cynomolgus monkeys | Q48638988 |
| Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs | Q48665583 | ||
| A fluvoxamine-caffeine interaction study | Q59915037 | ||
| American College of Clinical Pharmacology position statement on the use of microdosing in the drug development process | Q80050350 | ||
| Commentary on ACCP position statement on the use of microdosing in the drug development process | Q80119631 | ||
| Evaluation of microdosing strategies for studies in preclinical drug development: demonstration of linear pharmacokinetics in dogs of a nucleoside analog over a 50-fold dose range | Q80401257 | ||
| Microdose clinical trial: quantitative determination of fexofenadine in human plasma using liquid chromatography/electrospray ionization tandem mass spectrometry | Q81097075 | ||
| The utility of microdosing over the past 5 years | Q82758165 | ||
| Microdose pharmacokinetics of IDX899 and IDX989, candidate HIV-1 non-nucleoside reverse transcriptase inhibitors, following oral and intravenous administration in healthy male subjects | Q84582830 | ||
| Fluvoxamine inhibits the CYP2C9 catalyzed biotransformation of tolbutamide. | Q31945955 | ||
| The use of in vitro methods to predict in vivo pharmacokinetics and drug interactions | Q34341646 | ||
| Big physics, small doses: the use of AMS and PET in human microdosing of development drugs | Q35075780 | ||
| The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials | Q36611045 | ||
| Some pharmacokinetic aspects of the lipophilic terfenadine and zwitterionic fexofenadine in humans | Q36927601 | ||
| A pharmacokinetic evaluation of five H(1) antagonists after an oral and intravenous microdose to human subjects | Q37173944 | ||
| Single-dose escalation and multiple-dose safety, tolerability, and pharmacokinetics of IDX899, a candidate human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor, in healthy subjects | Q37190863 | ||
| Microdosing: A Valuable Tool for Accelerating Drug Development and The Role of Bioanalytical Methods in Meeting The Challenge | Q37810137 | ||
| New ultrasensitive detection technologies and techniques for use in microdosing studies | Q37810198 | ||
| Microdosing in early lead discovery | Q37810233 | ||
| Contribution of OATP (organic anion-transporting polypeptide) family transporters to the hepatic uptake of fexofenadine in humans | Q40398090 | ||
| The hepatic first-pass metabolism of problematic drugs | Q40843463 | ||
| Microdose clinical trial: quantitative determination of nicardipine and prediction of metabolites in human plasma | Q43278262 | ||
| Microdosing assessment to evaluate pharmacokinetics and drug metabolism in rats using liquid chromatography-tandem mass spectrometry. | Q46031834 | ||
| Use of accelerator mass spectrometry to measure the pharmacokinetics and peripheral blood mononuclear cell concentrations of zidovudine. | Q46125301 | ||
| P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion | Q46430437 | ||
| Evaluation of microdosing to assess pharmacokinetic linearity in rats using liquid chromatography-tandem mass spectrometry | Q46834857 | ||
| The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective | Q47819795 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 509-517 | |
| P577 | publication date | 2010-03-01 | |
| P1433 | published in | Bioanalysis | Q18616741 |
| P1476 | title | Microdosing: current and the future | |
| Microdosing: Current and The Future | |||
| P478 | volume | 2 |
| Q86903943 | A microdose study of ¹⁴C-AR-709 in healthy men: pharmacokinetics, absolute bioavailability and concentrations in key compartments of the lung |
| Q38186660 | Activating adaptive cellular mechanisms of resistance following sublethal cytotoxic chemotherapy: implications for diagnostic microdosing |
| Q48225243 | Deuterium- and Tritium-Labelled Compounds: Applications in the Life Sciences. |
| Q51744154 | Dose-dependent exposure and metabolism of GNE-892, a β-secretase inhibitor, in monkeys: contributions by P450, AO, and P-gp |
| Q35687753 | Human Tissue in the Evaluation of Safety and Efficacy of New Medicines: A Viable Alternative to Animal Models? |
| Q39324948 | Improved tumor contrast achieved by single time point dual-reporter fluorescence imaging. |
| Q38057372 | Induction of cytochrome P450 enzymes: a view on humanin vivofindings |
| Q39248701 | Intra-Target Microdosing (ITM): A Novel Drug Development Approach Aimed at Enabling Safer and Earlier Translation of Biological Insights Into Human Testing. |
| Q36287874 | Large Variation in Brain Exposure of Reference CNS Drugs: a PET Study in Nonhuman Primates |
| Q38660826 | Metabolite profiling in early clinical drug development: current status and future prospects |
| Q88084113 | Microdosing Cocktail Assay Development for Drug-Drug Interaction Studies |
| Q35940544 | Microdosing and drug development: past, present and future |
| Q34802510 | Phase 0 trials: expediting the development of chemoprevention agents |
| Q40034799 | Preclinical Characterization and Human Microdose Pharmacokinetics of ITMN-8187, a Nonmacrocyclic Inhibitor of the Hepatitis C Virus NS3 Protease |
| Q45348533 | Predicting drug candidate victims of drug-drug interactions, using microdosing |
| Q53099174 | Selected scientific topics of the 11th International Isotope Symposium on the Synthesis and Applications of Isotopes and Isotopically Labeled Compounds |
| Q82313034 | Sensitive determination of a pharmaceutical compound and its metabolites in human plasma by ultra-high performance liquid chromatography–tandem mass spectrometry with on-line solid-phase extraction |
| Q42730808 | Significant Species Difference in Amide Hydrolysis of GDC-0834, a Novel Potent and Selective Bruton's Tyrosine Kinase Inhibitor |
| Q50871327 | To Apply Microdosing or Not? Recommendations to Single Out Compounds with Non-Linear Pharmacokinetics |
Search more.